Research suggests that molnupiravir is effective against Omicron variant

摘要

The antiviral molnupiravir appears to remain effective against the Omicron variant of the SARS-CoV-2 virus, according to preliminary data, but monoclonal antibody treatments fare less well. The in vitro data, published in the New England Journal of Medicine on 26 January 2022 (https://www.nejm.org/doi/full/10.1056/NEJMc2119407) , appear to show molnupiravir and two other antivirals were just as effective against the Omicron variant as they were against earlier viral strains. Molnupiravir (MK-4482, EIDD-2801; MSD and Ridgeback Therapeutics) is licensed for use in the UK in at-risk populations, such as those with diabetes or heart disease. In its first month of use, up to 16 January 2022, 5,426 packs of molnupiravir were dispensed in England (/article/news/around-5000-courses-of-molnupiravir-dispensed-in-england-in-first-month-of-use) .